ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
Adeona Pharmaceuticals Common Stock

Adeona Pharmaceuticals Common Stock (AEN)

0,00
0,00
(0,00%)
Fermé 09 Janvier 10:00PM
0,00
0,00
(0,00%)
Après les heures de négociation: -

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
-
Prix Achat
-
Prix Vente
-
Volume échangé
-
0,00 Fourchette du Jour 0,00
0,00 Plage de 52 semaines 0,00
Clôture Veille
-
Ouverture
-
Dernière Transaction
Dernière heure de transaction
Volume moyen (3 m)
-
Volume financier
-
VWAP
-

AEN Dernières nouvelles

Adeona Becomes Synthetic Biologics, Inc.

Adeona Becomes Synthetic Biologics, Inc. -- New Name Reflects Biotechnology Company Focus on the Emerging Field of Synthetic Biologics -- -- New NYSE Amex Ticker Symbol: SYN -- PR Newswire ANN...

Adeona CEO to Present at the Harvard Investors Group Forum

Adeona CEO to Present at the Harvard Investors Group Forum PR Newswire ANN ARBOR, Mich., Feb. 9, 2012 ANN ARBOR, Mich., Feb. 9, 2012 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN...

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer

Adeona Appoints C. Evan Ballantyne as Chief Financial Officer -- Former CFO of Clinical Data, Inc. Brings Extensive Financial Background to Emerging Synthetic Biologics Company -- PR Newswire ANN...

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biolo...

Adeona Announces Executive Management Transitions and Board of Directors Appointments to Strengthen Company's Synthetic Biologics Strategic Focus -- Adeona Chairman, Jeff Riley, Appointed New...

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis

Adeona Announces Initiation of Phase II Clinical Trial of Trimesta™ for Cognitive Dysfunction in Multiple Sclerosis PR Newswire ANN ARBOR, Mich., Jan. 19, 2012 ANN ARBOR, Mich., Jan. 19, 2012...

Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice Pr...

Adeona Announces Proposed Name Change to Synthetic Biologics, Inc., and Appointment of John Monahan, Ph.D., as Senior Vice President of Research & Development -- Name Change Reflects Primary...

Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator

Positive Clinical Study Results Reported by Adeona's Oral Zinc for ALS Collaborator -- PNA Center for Neurological Research Clinical Study Results Presented at the 22nd International Symposium on...

Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary ...

Adeona Pharmaceuticals and Intrexon Announce Worldwide Exclusive Collaboration for Synthetic DNA-based Therapy for Pulmonary Arterial Hypertension PR Newswire ANN ARBOR, Mich., and GERMANTOWN...

Adeona Reports Third Quarter 2011 Financial Results

Adeona Reports Third Quarter 2011 Financial Results -- Clinical Trial for Cognitive Dysfunction in Multiple Sclerosis Recruiting Patients -- PR Newswire ANN ARBOR, Mich., Nov. 14, 2011 ANN ARBOR...

Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research

Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research PR Newswire ANN ARBOR, Mich., Nov. 11, 2011 ANN ARBOR, Mich., Nov. 11, 2011 /PRNewswire/ -- Adeona...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DE
40000000DE
120000000DE
260000000DE
520000000DE
1560000000DE
2600000000DE

AEN - Frequently Asked Questions (FAQ)

What is the current share price?
The current share price of is US$ 0,00
What is the 1 year trading range for share price?
has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
AAPYKurv Yield Premium Strategy Apple AAPL ETF
US$ 26,5099
(0,00%)
0
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 30,16
(0,00%)
0
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 26,42
(0,00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 26,33
(0,00%)
0
AAAAlternative Access First Priority CLO Bond ETF
US$ 25,125
(0,00%)
0
AAPYKurv Yield Premium Strategy Apple AAPL ETF
US$ 26,5099
(0,00%)
0
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 30,16
(0,00%)
0
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 26,42
(0,00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 26,33
(0,00%)
0
AAAAlternative Access First Priority CLO Bond ETF
US$ 25,125
(0,00%)
0
AAPYKurv Yield Premium Strategy Apple AAPL ETF
US$ 26,5099
(0,00%)
0
AAPXT Rex 2X Long Apple Daily Target ETF
US$ 30,16
(0,00%)
0
AAPRInnovator Equity Defined Protection ETF 2 Yr to April 2026
US$ 26,42
(0,00%)
0
AAAUGoldman Sachs Physical Gold ETF Shares
US$ 26,33
(0,00%)
0
AAAAlternative Access First Priority CLO Bond ETF
US$ 25,125
(0,00%)
0
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock